Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 25 |
| Active Pipeline (Recruiting Now) | 13 (9) |
| Completed vs Stopped Early | 2 / 0 (0.0%) |
| Median Closed Actual Enrollment | 110 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| National Cancer Center | Goyang-si | 12 |
| Asan Medical Center | Seoul | 3 |
| Ajou University Hospital | Suwon | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04214990 | Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Center, Korea Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.